<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04472676</url>
  </required_header>
  <id_info>
    <org_study_id>17611</org_study_id>
    <secondary_id>J2O-MC-EKBA</secondary_id>
    <secondary_id>2020-002522-91</secondary_id>
    <nct_id>NCT04472676</nct_id>
  </id_info>
  <brief_title>A Study of LY3473329 in Healthy Participants</brief_title>
  <official_title>A Safety, Tolerability, and Pharmacokinetic Study of Single-and Multiple-Ascending Doses of LY3473329 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study in healthy participants is to learn more about the safety of&#xD;
      LY3473329 and any side effects that might be associated with it. Blood tests will be&#xD;
      performed to check how much LY3473329 gets into the bloodstream and how long the body takes&#xD;
      to eliminate it. This is a two-part study. Participants may only enroll in one part.&#xD;
&#xD;
      For each participant:&#xD;
&#xD;
        -  Part A will last up to about 19 weeks and may include 9 visits.&#xD;
&#xD;
        -  Part B will last up to about 28 weeks and may include 11 visits.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 18, 2020</start_date>
  <completion_date type="Anticipated">December 7, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 8, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline up to Day 137</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3473329</measure>
    <time_frame>Baseline up to Day 137</time_frame>
    <description>PK: AUC of LY3473329</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Maximum Observed Drug Concentration (Cmax) of LY3473329</measure>
    <time_frame>Baseline up to Day 137</time_frame>
    <description>PK: Cmax of LY3473329</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">107</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3473329 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3473329 administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part A)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3473329 (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3473329 administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3473329</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3473329 (Part A)</arm_group_label>
    <arm_group_label>LY3473329 (Part B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Placebo (Part A)</arm_group_label>
    <arm_group_label>Placebo (Part B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females must adhere to contraception restrictions&#xD;
&#xD;
          -  Have clinical laboratory test results within normal reference range or with acceptable&#xD;
             deviations&#xD;
&#xD;
          -  Body mass index (BMI) less than or equal to (≤)30 kilograms per square meter (kg/m²)&#xD;
&#xD;
          -  For Part B:&#xD;
&#xD;
               -  Lipoprotein (a) (Lp[a]) greater than or equal to (≥)75 nanomoles per Liter&#xD;
                  (nmol/L) or 30 milligrams per deciliter (mg/dL) at screening&#xD;
&#xD;
               -  Plasminogen is within the normal range at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are currently enrolled in, or discontinued within the past 30 days from, a clinical&#xD;
             trial involving an investigational drug that has not received regulatory approval for&#xD;
             any indication, except for any trial involving antisense Lp(a), for which 6 months&#xD;
             must have passed from the participant's last study drug dose&#xD;
&#xD;
          -  Have previously completed or withdrawn from this study or any other study&#xD;
             investigating LY3473329&#xD;
&#xD;
          -  Are pregnant or breast feeding&#xD;
&#xD;
          -  Glomerular filtration rate (GFR) is lower than estimated GFR 60 milliliters per minute&#xD;
             per 1.73 square meters (mL/min/1.73 m2) using the Modification of Diet in Renal&#xD;
             Disease Study equation&#xD;
&#xD;
          -  Have a history or presence of medical illness including, but not limited to, any&#xD;
             cardiovascular, thromboembolism or bleeding disorder, hepatic, respiratory,&#xD;
             hematological, endocrine, immune, psychiatric or neurological disease, convulsions, or&#xD;
             any clinically significant laboratory abnormality that, in the judgment of the&#xD;
             investigator, indicate a medical problem that would preclude study participation&#xD;
&#xD;
          -  Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the&#xD;
             investigator, increases the risks associated with participating in the study. In&#xD;
             addition, participants with the following findings will be excluded: Confirmed&#xD;
             Fridericia's corrected QT interval greater than (&gt;)450 milliseconds (msec) for men and&#xD;
             &gt;470 msec for women. One additional ECG may be performed if required&#xD;
&#xD;
          -  Have an elevated high-sensitivity C-reactive protein (&gt;3 milligrams per Liter [mg/L])&#xD;
             or have a prothrombin time/international normalized ratio (PT/INR) or activated&#xD;
             partial thromboplastin time (aPTT) &gt;1.25 times (x) upper limit of normal (ULN)&#xD;
&#xD;
          -  Are an investigator or site personnel directly affiliated or immediate families.&#xD;
             Immediate family is defined as a spouse, parent, child or sibling, whether biological&#xD;
             or legally adopted&#xD;
&#xD;
          -  Are Lilly employees or contractors or an immediate family member of such&#xD;
&#xD;
          -  Show evidence of human immunodeficiency virus (HIV) and/or positive human HIV&#xD;
             antibodies, hepatitis C and/or positive hepatitis C antibody, or hepatitis B and/or&#xD;
             positive hepatitis B surface antigen&#xD;
&#xD;
          -  Have donated more than 500 milliliters (mL) of blood within the past month&#xD;
&#xD;
          -  Are unwilling to stop alcohol consumption while resident in the clinical research unit&#xD;
             (CRU)&#xD;
&#xD;
          -  Have an average weekly alcohol intake that exceeds 21 units per week (1 unit = 12&#xD;
             ounces [oz] or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled&#xD;
             spirits)&#xD;
&#xD;
          -  Have an abnormal blood pressure (supine) defined as diastolic blood pressure &gt;95 or&#xD;
             less than (&lt;)45 millimeters of Mercury (mmHg) and/or systolic blood pressure &gt;160 or&#xD;
             &lt;90 mmHg. Re-testing may occur once during screening within 2 hours of the initial&#xD;
             abnormal blood pressure measurement at the discretion of the investigator at screening&#xD;
&#xD;
          -  Have positive findings for known drugs of abuse on urinary drug screening&#xD;
&#xD;
          -  Positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus&#xD;
             nasopharyngeal polymerase chain reaction (PCR) test at Day -1&#xD;
&#xD;
          -  Contact with SARS-CoV-2- positive or corona virus disease 2019 (COVID-19) patient&#xD;
             within the last 14 days prior to admission to the clinical unit&#xD;
&#xD;
          -  In the opinion of the investigator or the sponsor, are unsuitable for inclusion in the&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>54 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>This is a single site clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Groningen</city>
        <zip>9728</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>00 310508505798</phone>
    </contact>
    <investigator>
      <last_name>Salah Hadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 1, 2021</verification_date>
  <study_first_submitted>July 14, 2020</study_first_submitted>
  <study_first_submitted_qc>July 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2020</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

